The inverted ILM flap technique yields better macular hole closure than ILM peeling for some high myopic macular holes.
University of Minnesota Medical School researchers have shown that reducing chronic inflammation can significantly protect against age-related macular degeneration (AMD)-like pathology in preclinical ...
Some people may worry about being bitten by a snake or spider, but have you ever considered what would happen if a small ...
Techno-Science.net on MSN
👁️ A subretinal implant partially restores vision in people with AMD
Age-related macular degeneration (AMD) causes progressive vision loss in a large number of elderly people, and no treatment ...
Retinal scans, aided by artificial intelligence (AI), may soon offer doctors a simple, non-invasive way to detect several ...
Public utility crews worked to repair a massive sinkhole that opened up next to a high school in Woodland Hills on Monday. The hole, caused by an apparent water main break, was first detected around ...
Lamellar hole-associated epiretinal proliferation (LHEP) is a distinctive clinical entity characterised by a homogeneous, medium-reflective material on optical coherence tomography that is commonly ...
Over 80% of Patients Demonstrated Meaningful Improvement of Visual Acuity and Were Able to Read Letters, Numbers, and Words Science is a leader in BCI technology and neural engineering. The PRIMA ...
Science Corp.’s PRIMA BCI Implant Restores Functional Central Vision to Patients with Geographic Atrophy Caused By Age-Related Macular Degeneration, a Leading Cause of Blindness, The New England ...
Age-related macular degeneration (AMD), the leading cause of blindness in adults over the age of 55, progressively degrades the macula, the part of the eye responsible for straight-ahead vision ...
– Vamikibart is the first non-steroid targeted therapy designed to address inflammation driving UME and may offer a potential new treatment option for patients – – Vision improvements were seen in ...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today results from two Phase III studies evaluating the efficacy and safety of two doses of investigational vamikibart (0 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results